Patent intelligence · EP
EP 2796145
EIN KOVALENTER KOMPLEX BESTEHEND AUS VON WILLEBRAND UND FAKTOR VIII VERBUNDEN MIT EINER DISULFIDBRÜCKE
EIN KOVALENTER KOMPLEX BESTEHEND AUS VON WILLEBRAND UND FAKTOR VIII VERBUNDEN MIT EINER DISULFIDBRÜCKE
Patent details — EP 2796145
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Oct 29, 2014
- Expiration
- Oct 24, 2034
- Applicant
- CSL BEHRING GMBH [DE]
- CPC classes
- A61K 38/ 37 A I, A61K/3836, A61K/3837, A61K/4755
Quick answer
EP 2796145 (EIN KOVALENTER KOMPLEX BESTEHEND AUS VON WILLEBRAND UND FAKTOR VIII VERBUNDEN MIT EINER DISULFIDBRÜCKE) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Oct 29, 2014. Expires Oct 24, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CSL BEHRING GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 37 A I, A61K/3836, A61K/3837, A61K/4755, A61K/4760, A61K/4762
More from CSL BEHRING GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2022258590
PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN
granted -
CA 3198740
METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS
granted -
AU 2017305856
Pharmaceutical formulations of C1 esterase inhibitor
granted -
DK 2928905
FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER
granted -
CA 3072003
PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND
granted -
US 2018264111
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS
granted -
CA 3046406
PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES
granted -
CA 3034568
PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE
granted
Frequently asked questions
What is US patent 2796145?
EP 2796145 (EIN KOVALENTER KOMPLEX BESTEHEND AUS VON WILLEBRAND UND FAKTOR VIII VERBUNDEN MIT EINER DISULFIDBRÜCKE) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Oct 29, 2014. Expires Oct 24, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2796145?
CSL BEHRING GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2796145 expire?
Our index shows an expiration date of Oct 24, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.